RECENT Healthcare RESEARCH
Incyte reported revenues of ~$326.4 million for 2Q17, compared with ~$246.3 million for 2Q16.
Allergan reported an 8.8% increase in its 2Q17 revenues to $4.0 billion as compared to $3.7 billion in 2Q16.
JAZZ is now engaged in patent litigations involving Xyrem in the US with four other generic players.
In fiscal 4Q17, Medtronic’s revenue came in at $7.9 billion, representing YoY (year-over-year) growth of ~5%.
In 1H17, Fresenius Medical Care (FMS) reported revenues close to 9.0 billion euros, which represents 14% YoY growth. At the end of 2Q17, the company operated 3,690 dialysis clinics around the world.
Sanofi (SNY), one of the world’s largest pharmaceutical companies, reported operational growth of 5.5% to reach revenue of 8.7 billion euros in 2Q17.
Dentsply Sirona (XRAY) reported its 2Q17 earnings on August 9. The company earned revenues of ~$992.7 million, registering a year-over-year decline of ~2.9%.
Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”
Of the 13 analysts covering Align Technology in August 2017, eight rated the company a “strong buy,” and five rated it a “buy.”
With the spin-off of its Imaging Components business, Varian Medical Systems (VAR) is now more aligned with its core capabilities. In this series, we’ll discuss the company’s dynamics after the Varex spin-off.
Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16.
In 2Q17, Alexion Pharmaceuticals (ALXN) reported revenues close to $912.0 million, which is a YoY (year-over-year) rise of 21.0%.
Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”
Varian Medical Systems (VAR) reported its 3Q17 earnings on July 26, 2017. It reported revenues of $662.4 million, a rise of ~3.0% on a YoY basis.
In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.
Twenty-five analysts covered Gilead Sciences (GILD) in July 2017. One analyst recommended a “strong buy,” ten analysts recommended a “buy,” and 14 analysts recommended a “hold” on the stock.
In 2Q17, Edwards Lifesciences (EW) reported revenues close to $842 million. The company reported underlying year-over-year revenue growth of ~15% in 2Q17.
In its earnings release on July 26, GlaxoSmithKline (GSK) reported 12% growth to ~7.3 billion pounds in its 2Q17 revenues. GSK surpassed analysts’ estimates for revenues and earnings per share.
Pfizer (PFE) is set to release its 2Q17 earnings on August 1, 2017. Analysts estimate earnings per share of $0.66 on revenues of ~$13.1 billion for 2Q17.
Bristol-Myers Squibb’s top line rose nearly 6% to ~$5.1 billion in 2Q17 due to operational growth of 7% in its revenue.